Search
Emicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalThe ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents. … [A31279, L1016] It was created by Chugai Pharmaceuticals Co. Ltd. and co-developed with Roche and Genentech.[L1015]
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalLike other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. … In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMivacurium
go.drugbank.com/drugs/DB01226ApprovedWithdrawnIt binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigationalObinutuzumab is a humanized anti-CD20 monoclonal antibody designed to treat B-cell malignancies. … [L54521] It was developed as a Type II anti-CD20 antibody to improve upon first-generation agents like rituximab.
Ipratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigationalIpratropium is a quaternary ammonium derivative of atropine that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption....
Categories: Agents to Treat Airway DiseaseFlutemetamol (18F)
go.drugbank.com/drugs/DB09151ApprovedInvestigationalIt is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029] … Flutemetamol (18F), an analogue of [(11)C]PIB,[A18519] is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density.
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationaldue to non-selective steroidal activities [A275513, A275514]. … Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512].
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalEtrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub … [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Phenylalanine
go.drugbank.com/drugs/DB00120ApprovedInvestigationalNutraceuticalPhenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.
Mixtures: Nutriflex Lipid special ohne Elektrolyte Emulsion zur Infusion, Nutriflex Omega special ohne Elektrolyte B. Braun Emulsion zur InfusionFenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawnDravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. … [A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome